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Translational Relevance 
 In this study, we show that NADH Dehydrogenase (Ubiquinone) 1 alpha 
subcomplex 4-like 2 (NDUFA4L2) is a novel molecular target for clear cell renal 
cell carcinoma (ccRCC) treatment. We demonstrate that NDUFA4L2 is highly 
expressed at the mRNA and protein levels in human ccRCC, yet is not 
expressed in normal, healthy kidney tissue. We also show that NDUFA4L2 
mRNA expression is high across all stages of ccRCC compared to normal kidney, 
with an even greater expression in higher stage ccRCC. Additionally, patients 
with the highest expression of NDUFA4L2 in their tumors exhibit a lower overall 
survival. Knockdown of NDUFA4L2 in cell culture models of ccRCC greatly 
impairs proliferation, perturbs metabolic pathways, and causes major stress on 
RCC cells.  
Abstract 
Purpose: We delineated the functions of the HIF1α target NADH 
Dehydrogenase (Ubiquinone) 1 alpha subcomplex 4-like 2 (NDUFA4L2) in 
ccRCC and characterized NDUFA4L2 as a novel molecular target for ccRCC 
treatment. 
Experimental Design: We evaluated normal kidney and ccRCC patient 
microarray and RNAseq data from Oncomine and The Cancer Genome Atlas 
(TCGA) for NDUFA4L2 mRNA levels and the clinical implications of high 
NDUFA4L2 expression. Additionally, we examined normal kidney and ccRCC 
patient tissue samples, human ccRCC cell lines, and murine models of ccRCC 
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for NDUFA4L2 mRNA and protein expression. Utilizing shRNA, we performed 
NDUFA4L2 knockdown experiments and analyzed the proliferation, clonogenicity, 
metabolite levels, cell structure, and autophagy in ccRCC cell lines in culture.   
Results: We found that NDUFA4L2 mRNA and protein are highly expressed in 
ccRCC samples but undetectable in normal kidney tissue samples, and that 
NDUFA4L2 mRNA expression correlates with tumor stage and lower overall 
survival. Additionally, we demonstrated that NDUFA4L2 is a HIF1α target in 
ccRCC and that NDUFA4L2 knockdown has a profound anti-proliferative effect, 
alters metabolic pathways, and causes major stress in cultured RCC cells.  
Conclusions: Collectively, our data show that NDUFA4L2 is a novel molecular 
target for ccRCC treatment.  
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Introduction  
Clear cell renal cell carcinoma (ccRCC) is the most common form of 
kidney cancer, representing more than 80% of all diagnoses (1). ccRCC is a 
disease of altered cell metabolism (2), and many genes known to contribute to 
the development and/or progression of ccRCC are involved in sensing oxygen, 
iron, nutrients, and energy (3). Altered metabolism is now a widely accepted 
hallmark of cancer (4), and metabolic alterations greatly influence tumor 
development and progression (5). Thus, targeting metabolic abnormalities in 
ccRCC may provide novel opportunities for developing more effective treatments 
(2).  
The majority of ccRCCs possess an inactivating mutation in the von 
Hippel-Lindau (VHL) tumor suppressor gene, which leads to the stabilization of 
hypoxia inducible factors (HIFs) (6, 7). HIF1α and HIF2α are transcription factors 
that influence expression of many genes involved in altered metabolic pathways 
in cancer, including glucose uptake, enhanced glycolytic metabolism, and 
decreased mitochondrial respiration (8). We previously demonstrated that 
expression of a constitutively active HIF1α mutant protein exclusively in kidney 
proximal tubule cells is sufficient to drive a program of early tumorigenesis in a 
murine model of ccRCC called the TRACK (TRAnsgenic model of Cancer of the 
Kidney) model (9). TRACK mice exhibit increased expression of HIF1α target 
genes that are associated with a shift in metabolism from mitochondrial oxidative 
phosphorylation to increased aerobic glycolysis and lactate production, similar to 
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what is observed in human ccRCC (10). Additionally, our metabolomics data 
show that TRACK kidneys and human ccRCC samples have increased levels of 
glycolytic intermediates and lactate, and decreased levels of metabolites of the 
TCA cycle (10). Similar to our findings in the TRACK kidneys, Arreola et al. found 
that stable expression of HIF1α in primary kidney epithelial cells increased 
expression of key glycolytic enzymes and favored pyruvate conversion into 
lactate under nutrient poor conditions (11). In contrast, stable expression of 
HIF2α in primary kidney epithelial cells did not appear to mediate glycolysis or 
inhibit oxidative phosphorylation (11). Indeed, HIF2α had minimal influence on 
glycolysis and was found to support oxidative phosphorylation in a nutrient rich 
environment (11).   
In the current study we evaluated the levels and role of the gene NADH 
dehydrogenase (ubiquinone) 1 alpha subcomplex 4-like 2 (NDUFA4L2, Gene ID: 
56901). NDUFA4L2 is one of the most highly expressed genes in almost all 
ccRCC samples compared to healthy kidney tissue, according to several sets of 
microarray data from the Oncomine database (12-15) and RNA sequencing 
(RNAseq) data from The Cancer Genome Atlas (TCGA) (16, 17), and 
NDUFA4L2 expression is similarly increased by >50 fold in TRACK kidneys (10, 
16). Hypoxia induces NDUFA4L2 expression via a mechanism involving HIF1α, 
but not HIF2α (18). Blocking HIF1α by RNA interference abrogated NDUFA4L2 
expression in a VHL negative ccRCC cell line, whereas blocking HIF2α 
expression by RNA interference did not affect the expression of NDUFA4L2 (18). 
Under hypoxic conditions NDUFA4L2 is involved in lowering mitochondrial 
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oxygen consumption and Complex I mitochondrial activity, which in turn causes a 
shift from mitochondrial respiration to anaerobic glycolysis and reduces ROS 
production (18). Thus, NDUFA4L2 plays a role in altering cellular metabolism 
when HIF1α is stabilized and active within a cell. In the current study we 
analyzed the functions of NDUFA4L2 in ccRCC. 
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Materials and Methods 
Analysis of published data 
 The Oncomine database was used to compare microarray data from 
human ccRCC samples and matched normal kidney tissue (19). We analyzed 
the most highly expressed transcripts in tumors compared to normal kidney 
tissue in four studies (12-15).  
 Clinical parameters and next generation RNA sequencing data 
(RNAseqv2) were obtained from TCGA ccRCC and matched normal kidney 
tissue (KIRC) sample set. Normalized gene counts (gene counts re-scaled 
according to library size) from each patient were compiled into a tab-delimited file 
for downstream analysis by EdgeR software (20) and hierarchical cluster 
analysis completed using Cluster3.0 (21). Clinical data used for these studies 
include the American Joint Committee on Cancer (AJCC) stage and Fuhrman 
grade of the sequenced tumors and the survival status of the patient from which 
the tumor was removed.  
 We used the integrated genome viewer to analyze a published 
HIF1α ChIPseq (chromatin immune-precipitation coupled with next generation 
sequencing) dataset (GEO: GSE39089) in the context of the HG18 genome build 
(22). These data were performed to assess HIF1α binding in human umbilical 
vein endothelial cells in hypoxic and normoxic conditions.  
Tissue samples  
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Human tissue samples were obtained from patients who underwent 
radical or partial nephrectomy at Weill Cornell Medical College (WCMC). The 
pathologist selected samples of tumor and normal kidney tissue to be used for 
research. The Institutional Review Board at WCMC approved this study.  
 Male C57BL/6 wild type mice were obtained from Jackson Laboratories 
and TRACK mice were generated as described (9). All procedures involving the 
use of mice were approved by the WCMC Institutional Animal Use and Care 
Committee.  
Cell Proliferation and Colony Formation Assays 
RCC4 (ATCC) and SKRC48 (Sloan Kettering Institute, not authenticated) 
cell lines were cultured in DME medium (MP Biomedicals; 1033122) containing 
10% fetal bovine serum (Gibco, Life Technologies; 10439-016), Caki1 cells 
(ATCC) were grown in McCoy's 5a Medium Modified (Gibco; 16600-082) 
containing 10% fetal bovine serum, and 786-O and HK2 cells (ATCC) were 
grown in RPMI-1640 medium (Gibco; 11875-093) containing 10% fetal bovine 
serum.  Cells were cultured in a humidified tissue culture incubator at 37oC in a 
10% CO2 atmosphere. 
For proliferation assays, cells were plated at 2.5 x 104 per well in multi-well 
culture plates. Cell numbers were counted in triplicate using an electron particle 
counter (Coulter Z; Beckman Coulter) after 1, 3, 5, and 7 d of culture. For colony 
formation assays, cells were plated at 500 per 6-well plate. After approximately 
14 days, cells were stained with crystal violet. The number of colonies was 
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quantified using ImageJ software (National Institutes of Health). 
  
Knockdown of NDUFA4L2 using shRNA  
 We produced shRNA containing lentiviral particles as described (23). We 
used two pLKO shNDUFA4L2 vectors directed specifically towards human 
NDUFA4L2 (Sigma Aldrich; TRCN0000046592 and TRCN0000046589) or a 
pLKO non-targeting shRNA plasmid (control) (Supplementary Table S1). RCC4, 
SKRC48, Caki1, 786-O, and HK2 cell lines were infected with shRNA lentiviral 
particles, and 4 μg/mL polybrene (Aldrich; 107689) for 24 hours. After infections, 
cells were treated with 2 μg/mL (SKRC48, Caki1, and HK2) or 4 μg/mL (RCC4 
and 786-O) puromycin (Sigma; P8833) for 4 days and knockdown was assessed 
by Western blotting.  
Western blot analysis 
Proteins were extracted in SDS final sample buffer, boiled, separated on 
SDS-PAGE gels, and transferred onto nitrocellulose membranes. Membranes 
were probed with primary antibodies (Supplementary Table S2) overnight at 4oC, 
and further incubated with secondary antibody at 22°C for 1 h. 
Chemiluminescence was recorded with a quantitative gel imaging station (Bio-
Rad ChemiDoc) and data were analyzed using Image Lab software (Bio-Rad).  
RNA isolation and PCR reactions 
Total RNA was isolated using TRIzol reagent (Ambion, Life Technologies; 
15596018). mRNA (5 μg) was reverse transcribed using the qScript cDNA 
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SuperMix (Quanta Biosciences; 95048) (24). Semi-quantitative RT-PCR 
reactions were performed with 2 μg cDNA as template using a BioRad iCycler 
(25). All primers were designed around introns (Supplementary Table S3).   
Metabolomics analysis  
 Cells were plated on 10-cm plates and metabolites were extracted 
following established protocols using 80% methanol (cooled to -80°C) (10, 26). 
Metabolites were dried using a SpeedVac (Savant) and stored at -80°C until 
being shipped on dry ice to the Metabolomics Core Facility at Beth Israel 
Deaconess Medical Center (BIDMC). Targeted mass spectrometry was 
performed by the BIDMC core facility to analyze metabolites (26).  
 Metabolomics data were processed, normalized to protein, and analyzed 
using the MetaboAnalyst program (27) For statistical analyses, one-way ANOVA 
was performed on parental RCC4 vs. shNDUFA4L2.1 treated cells and on shCTL 
treated vs. shNDUFA4L2.1 treated cells. Metabolites that were significantly 
altered (p<0.05) in shNDUFA4L2.1 treated cells compared to both parental and 
shCTL treated cells were evaluated and used for pathway analysis.    
Electron microscopy 
Cells were plated on a 6-well plate and grown to approximately 90% 
confluence. Cells were fixed in 2.5% glutaraldehyde, 4% paraformaldehyde, and 
0.02% picric acid in 0.1M sodium cacodylate buffer, pH 7.3 for at least 1 hour at 
4°C (28). The plates were processed and embedded in EMbed 812 resin 
(Electron Microscopy Sciences) as previously described (29). Images were taken 
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by the WCMC Electron Microscopy & Histology core facility on a JSM 100-CX 
transmission electron microscope (JEOL USA, Inc.).  
For each cell type, three images were taken of five different cells (15 
images total/cell type). Analyses of images were performed in a blinded manner 
with respect to sample identity. Swollen mitochondria were defined as large, 
round in shape with few, disorganized cristae. Improved mitochondria were 
contracted and regular in shape, with more organized cristae. Autophagosomes 
were defined as vacuoles with double membranes and/or undigested materials, 
and autolysosomes were defined as vacuoles with single membranes and 
amorphous electron-dense regions (30). 
Statistical analyses 
 Student’s t-test was performed on at least three separate, independent 
experiments (n=3 or >3) using the Graph Pad Prism 6.0 software. Metabolomics 
data were analyzed with MetaboAnalyst (27) and RNAseq data were analyzed 
with EdgeR software (Bioconductor) (20). 
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Results 
NDUFA4L2 mRNA and protein levels are increased in human ccRCC 
To identify potentially important genes that contribute to renal 
carcinogenesis, we first searched the Oncomine database of published 
microarray data from matched malignant and non-malignant samples (19). We 
analyzed four studies that in total compared gene expression data from 69 
ccRCC samples and 45 adjacent, non-tumor kidney samples (12-15) (Table 1). 
Additionally, we collected TCGA RNAseqV2 data from 530 ccRCC samples and 
72 adjacent non-tumor samples (Table 1) (17). In each of these studies, one 
gene in particular, NDUFA4L2, stood out as having a strikingly large fold 
increase in ccRCC. Indeed, Yusenko et al. (14) found that NDUFA4L2 transcripts 
are increased by nearly 90-fold in ccRCC compared to non-tumor kidney 
samples (Table 1). Additionally, ~90% of the 530 ccRCC samples for which 
RNAseq data is available in TCGA possessed elevated NDUFA4L2 expression 
(17). Although NDUFA4L2 mRNA is considerably increased in ccRCC compared 
to normal kidney tissue according to microarray and RNAseq data, this gene has 
not been well characterized and its role in ccRCC has not been thoroughly 
defined. 
Following this analysis of published mRNA expression data, we evaluated 
both NDUFA4L2 mRNA and protein levels in human ccRCC tumors and matched 
non-tumor kidney tissue by performing semi-quantitative PCR and Western blot 
analyses, respectively. We found that NDUFA4L2 transcripts were highly 
elevated in tumors compared to normal, adjacent kidney tissue (Fig. 1A, left 
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panel). Tumor 1 has an approximately 20-fold and tumor 2 a ~30-fold increase in 
NDUFA4L2 transcripts compared to non-malignant kidney tissue samples from 
the same patients. Additionally, we show that NDUFA4L2 protein (~13 kDa) is 
highly expressed in tumor samples from patients 3, 4, and 5 (Fig. 1A, right panel). 
Quantitation of bands indicates that NDUFA4L2 protein is increased by 10 to 30-
fold in tumors compared to adjacent non-malignant kidney tissue. These mRNA 
and protein data from human patient samples are striking, as NDUFA4L2 is 
highly expressed in each of the five tumor samples, and is barely detectable in 
each of the non-malignant renal tissue samples under our conditions for PCR 
and western blotting (Fig. 1A). These data also suggest that elevated expression 
of NDUFA4L2 is a common event in ccRCC and that expression is restricted to 
the tumors. 
To identify relevant cell line models to utilize in further experimentation, we 
evaluated NDUFA4L2 at the mRNA and protein levels in various human clear cell 
renal cell carcinoma cell lines and a normal, non-transformed human proximal 
tubule cell line, HK2 (Fig. 1B). RCC4 and SKRC48 ccRCC cell lines  have 
activated HIF1α and thus we detected NDUFA4L2 mRNA and protein in these 
cells (Fig. 1B).  We did not detect NDUFA4L2 mRNA in the ccRCC cell lines 
Caki1 and 786-O, in which HIF1α is not active, nor in the normal proximal tubule 
cell line HK2 (Fig. 1B). Based on high NDUFA4L2 expression, we chose to use 
the RCC4 and SKRC48 cell lines as in vitro ccRCC models for further studies. 
The commercially available antibodies targeting NDUFA4L2 
(Supplementary Table S1) also detect NDUFA4 (~10 kDa) (Fig. 1A,B, right 
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panels). NDUFA4L2 and NDUFA4 have high homology at the C-terminus, the 
region of the NDUFA4L2 protein that the antibodies recognize. NDUFA4 was 
recently shown to be a subunit of mitochondrial Complex IV (cytochrome c 
oxidase) (31). NDUFA4 protein is decreased in the tumor samples by 
approximately 10 to 30-fold (Fig. 1A, right panel) and by approximately 5-fold in 
RCC4 and SKRC48 cells compared to Caki1 cells (Fig. 1B, right panel).  
Increased NDUFA4L2 expression correlates with more advanced human 
ccRCC stage, grade, and reduced survival  
 To assess if increased NDUFA4L2 expression in ccRCC had any clinical 
relevance, we evaluated TCGA RNAseq data and corresponding clinical 
parameters (17). For our study, level 2 RSEM normalized expression count data 
were obtained from the TCGA. With regard to available clinical information, we 
prioritized tumor AJCC stage, Fuhrman grade, and survival data from patients 
with histologically confirmed ccRCC. AJCC staging is the most important factor 
predicting prognosis and it is based on tumor size and metastatic involvement 
(32). Patient:stage distributions were: stage I (n=253), stage II (n=56), stage III 
(n=125) and stage IV (n=81). Stage III ccRCCs have a ~25% increase in 
NDUFA4L2 mRNA expression compared to stages I and II (Fig. 1C). Fuhrman 
grading, which refers to how closely the cancer cells look like normal kidney cells 
under a microscope, is another important prognosis factor. Patient:grade 
distributions were: grade I (n=11), grade II (n=229), grade III (n=203), grade IV 
(n=75). Grade III ccRCCs have a ~35% increase in NDUFA4L2 mRNA 
expression compared to stage II (Fig. 1D). 
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 Next, we evaluated overall survival based on NDUFA4L2 mRNA levels 
(Fig. 1E). Notably, nearly all ccRCC samples (~90%) have high NDUFA4L2. 
Consequently, we defined two patient subgroups based on normalized 
NDUFA4L2 expression, (i) patients with lower NDUFA4L2 expression (counts < 
60,000; n= 448), and (ii) patients with higher NDUFA4L2 expression (normalized 
count > 60,000; n= 60), which is >90-fold higher NDUFA4L2 expression than in 
normal kidney tissue. We found that patients with the highest NDUFA4L2 mRNA 
levels exhibited lower overall survival compared to patients with lower 
NDUFA4L2 mRNA (log rank test; p= 0.0011) (Fig. 1E). For patients with lower 
NDUFA4L2 expression, the median survival is 2454 days, and for patients with 
the highest NDUFA4L2 expression the median survival is 1111 days (Fig. 1E).  
NDUFA4L2 is HIF1α regulated in ccRCC 
It was previously reported that NDUFA4L2 is a direct HIF1α target under 
hypoxic conditions (18). To validate HIF1α regulation of NDUFA4L2 in ccRCC we 
assessed NDUFA4L2 expression in the kidneys of the TRACK murine model of 
ccRCC, as well as in HIF2αM3 transgenic positive (TG+) and transgenic 
negative (TG-) mice. TRACK mice express a constitutively active form of HIF1α 
specifically in proximal tubule cells and HIF2αM3 TG+ mice express a 
constitutively active form of HIF2α specifically in proximal tubule cells (9, 33). We 
previously reported that TRACK mice display a tumorigenesis program that more 
closely resembles early human ccRCC than HIF2αM3 TG+ mice (9, 10, 16, 33, 
34). We found that NDUFA4L2 expression is regulated by HIF1α and not HIF2α, 
Research. 
on January 26, 2016. © 2016 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on January 18, 2016; DOI: 10.1158/1078-0432.CCR-15-1511 
 16
as NDUFA4L2 transcripts and protein are highly expressed in the TRACK 
kidneys, but not in HIF2αM3 TG+ or TG- mouse kidneys (Fig. 2A). Additionally, 
western blot analyses of different tissues from TRACK mice indicate that 
NDUFA4L2 expression is unique to the kidneys where constitutively active HIF1α 
is specifically expressed (Fig. 2B). NDUFA4L2 protein cannot be detected in the 
normal pancreas, liver, heart, lung, testes, or intestines of TRACK mice (Fig. 2B).  
To determine whether HIF1α plays a role in direct regulation of 
NDUFA4L2, we used the integrated genome viewer to analyze a published 
HIF1α ChIPseq (chromatin immune-precipitation coupled with next generation 
sequencing) dataset (GEO: GSE39089) (22). These data indicate that HIF1α is 
recruited to the NDUFA4L2 locus in hypoxic human umbilical vein endothelial 
cells (Supplementary Fig. S1A). It is therefore likely that HIF1α plays a similar 
role in kidney proximal tubule epithelial cells. Additionally, hierarchical clustering 
analysis of the TCGA ccRCC dataset shows that NDUFA4L2 clusters with other 
known HIF1α target genes in ccRCC, such as VEGFA, HK2, and SLC16A3 
(Supplementary Fig. S1B). 
NDUFA4L2 knockdown impairs cell proliferation and colony formation in 
ccRCC cell lines 
To assess the functional significance of NDUFA4L2 in ccRCC, we 
performed knockdown of NDUFA4L2 with two independent shRNAs via 
lentivirus-mediated infection in RCC4 and SKRC48 ccRCC cells that express 
NDUFA4L2 (Fig. 1B). We confirmed NDUFA4L2 knockdown by >90% at the 
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protein level with both NDUFA4L2 shRNA targeting constructs, shNDUFA4L2.1 
and shNDUFA4L2.2, by Western blotting. No changes in NDUFA4L2 levels were 
observed when RCC4 and SKRC48 cells were infected with a non-targeted 
control hairpin (shCTL) (Fig. 3A).  
We next analyzed the growth characteristics of ccRCC cells that lack 
NDUFA4L2 expression. Both RCC4 and SKRC48 cells infected with 
shNDUFA4L2 constructs showed reduced proliferation over 7 days compared to 
the parental or shCTL-treated cells (Fig. 3B). In both RCC4 and SKRC48 cell 
lines, shNDUFA4L2.1 treatment reduced cell proliferation by more than 60% and 
shNDUFA4L2.2 treatment reduced cell proliferation by approximately 90% (Fig. 
3B).  
As further confirmation of the importance of NDUFA4L2 for cell 
proliferation, we assayed for clonogenic growth in RCC4 and SKRC48 cells 
lacking NDUFA4L2 expression. Consistent with the proliferation assays, 
NDUFA4L2 knockdown greatly diminished the capacity of cells to form colonies 
(Fig. 3C), reducing the numbers of colonies by > 90% (Fig. 3D). Collectively, the 
proliferation and colony formation assays show that NDUFA4L2 expression 
promotes cell proliferation and clonogenic growth of VHL-negative ccRCC cells.  
 We also performed viral infection with the shCTL, shNDUFA4L2.1, and 
shNDUFA4L2.2 constructs in Caki1 and 786-O ccRCC cell lines and HK2, a non-
transformed proximal tubule cell line, which do not express NDUFA4L2 (Fig. 1B). 
We found that treatment with the shCTL and shNDUFA4L2.1 constructs had no 
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effect on proliferation and clonogenicity (Supplementary Fig. S2A,B). Treatment 
with the shNDUFA4L2.2 construct impaired proliferation by ~30-50% in the Caki1 
and 786-O cell lines and impaired clonogenicity by ~80% in Caki1 cells 
(Supplementary Fig. S2A,B). However, the shNDUFA4L2.2 did not impair 
proliferation in the HK2 normal proximal tubule cell line (Supplementary Fig. S2A). 
These data suggest that the Caki1 and 786-O cell lines have low levels of 
NDUFA4L2 not detectable in our assays or that shNDUFA4L2_2 has an 
additional off-target effect. 
NDUFA4L2 knockdown alters metabolic pathways 
 To evaluate why NDUFA4L2 is critical for proliferation and clonogenic 
growth of RCC4 and SKRC48 cells, we next evaluated changes in metabolite 
levels upon NDUFA4L2 knockdown. Under hypoxic conditions, NDUFA4L2 
inhibits Complex I of oxidative phosphorylation and thus mediates a cellular shift 
to glycolysis for generating ATP (18). ccRCC is widely characterized as a 
metabolic cancer that relies on glycolysis instead of oxidative phosphorylation to 
produce ATP (3), which is an adaptive measure to facilitate the uptake and 
incorporation of nutrients into biomass in order to produce new cells (35).  
 A metabolomics analysis demonstrated that RCC4 cells treated with 
shNDUFA4L2.1 showed increases in the levels of several tricarboxylic acid 
(TCA) cycle intermediates and decreases in the levels of several pentose 
phosphate pathway intermediates compared to parental and shCTL treated cells 
(Fig. 4A,B). With respect to the TCA cycle, we observed 2-fold or greater 
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increases in the levels of citrate/isocitrate, α-ketoglutarate, succinate, and 
oxaloacetate (Fig. 4A). In contrast, we saw marked decreases in the pentose 
phosphate pathway intermediates ribose 5-phosphate, sedoheptulose 1,7-
bisphosphate, glyceraldehyde 3-phosphate, and fructose 6-phosphate (Fig. 4B). 
These data suggest that upon NDUFA4L2 knockdown, pyruvate generated by 
the glycolysis pathway is converted to acetyl-CoA to fuel the TCA cycle and as 
such, glycolytic intermediates are not shunted into the pentose phosphate 
pathway (Fig. 4C). This is important because proliferating cancer cells shunt 
glycolytic metabolites into the pentose phosphate pathway to make ribose-5-
phosphate, which is needed for nucleic acid production (35). Ribose 5-phosphate 
is 1.6-fold lower in shNDUFA4L2.1 treated RCC4 cells compared to shCTL 
treated cells, and 2.2-fold lower compared to parental RCC4s (Fig. 4B). 
Additionally, a principal component analysis showed that RCC4 parental and 
shCTL treated cells cluster distinctly from RCC4 cells treated with 
shNDUFA4L2.1 (Supplementary Fig. S3A), and pathway analysis of significantly 
altered metabolites in the RCC4 cells treated with shNDUFA4L2.1 compared to 
the parental and shCTL treated cells demonstrated that two of the most 
significantly altered metabolic pathways were metabolism of pyrimidine and 
purine nucleotides (Supplementary Fig. S3B). Thus, the metabolomics data 
demonstrate that NDUFA4L2 knockdown alters metabolism in a manner such 
that the pentose phosphate pathway is down-regulated and less ribose 5-
phosphate is being produced, which in turn likely reduces purine and pyrimidine 
synthesis.  
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NDUFA4L2 knockdown improves mitochondrial morphology and induces 
autophagy  
 Cancer cells that have a reduced capacity for aerobic respiration also 
exhibit abnormalities in both the content and composition of their mitochondria 
(36). We hypothesized that NDUFA4L2 inhibits aerobic respiration in ccRCC, and 
that elevated expression of NDUFA4L2 contributes to abnormal mitochondrial 
structure. When we analyzed RCC4 parental, shCTL-treated, and NDUFA4L2 
knockdown cells by transmission electron microscopy (TEM), we found that 
RCC4 parental and shCTL treated cells had many swollen mitochondria with 
disorganized cristae (Fig. 5A, filled arrows). However, RCC4 cells treated with 
both shNDUFA4L2 constructs had more contracted mitochondria with improved 
cristae (Fig. 5A, open arrows). Indeed, approximately 50% of the mitochondria in 
parental and shCTL treated RCC4 cells are swollen with disorganized cristae, 
while less than 10% display this morphology in cells treated with shNDUFA4L2.1 
and shNDUFA4L2.2 (Fig. 5B). Though the morphology of the mitochondria is 
changed when NDUFA4L2 levels are reduced, the numbers of mitochondria 
remain the same (Fig. 5C).  
NDUFA4L2 knockdown also promotes autophagy, a process by which 
cytosolic components are engulfed in double-membrane autophagosomes that 
fuse with lysosomes for degradation (37), and mitochondrial turnover is 
dependent on autophagy (38). In RCC4 cells treated with both shNDUFA4L2 
constructs, we visualized many autophagosomes (Fig. 5A, filled stars) as defined 
by vacuoles with double membranes and/or undigested materials, and 
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autolysosomes (Fig. 5A, open stars) as defined by vacuoles with single 
membranes and amorphous electron-dense regions (30). We detected a 3.8 
(±1.3) -fold increase in autophagosomal vesicles in RCC4 cells treated with 
shNDUFA4L2.1 and a 5.1 (±1.6) –fold increase in shNDUFA4L2.2 treated cells 
compared to parental cells (Fig. 5D). Additionally, we counted more 
autolysosomes than autophagosomes in RCC4 cells treated with shNDUFA4L2.1 
and shNDUFA4L2.2 (Fig. 5D).  
LC3, or tubule-associated protein 1/A/1B-light chain 3, is a biomarker of 
autophagy. During autophagy, the cytosolic form of LC3 (LC3-I) is converted to 
its lipidated form, LC3-II, which is recruited to autophagosomal membranes. We 
detected a >8-fold induction of LC3-II in both RCC4 and SKRC48 lines treated 
with shNDUFA4L2.1 and shNDUFA4L2.2 compared to the parental and shCTL-
treated cells (Fig. 5E). Together, the improved mitochondrial structures and the 
induction of autophagy upon NDUFA4L2 knockdown suggest that NDUFA4L2 
knockdown promotes mitochondrial turnover via autophagy.  
We also analyzed Caki1 cells, which do not have elevated expression of 
NDUFA4L2 (Fig. 1B), to determine if shRNA treatment improves mitochondria 
morphology and/or induces autophagy. We found that mitochondria in Caki1 
parental and Caki1 cells treated with shCTL, shNDUFA4L2.1, and 
shNDUFA4L2.2 have contracted mitochondria with typical cristae 
(Supplementary Fig. S4A). There was no improvement in mitochondrial 
morphology in Caki1 upon treatment with either shNDUFA4L2 construct 
(Supplementary Fig. S4A). 
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Next, we evaluated the numbers of autophagic vacuoles in Caki1 parental 
and shRNA treated cells.  We found that Caki1 cells treated with shNDUFA4L2.2 
had more autophagic vacuoles than Caki1 parental cells and cells treated with 
shCTL and shNDUFA4L2.1 (Supplementary Fig. S4B). However, the increase in 
autophagic vacuoles seen in Caki1 cells treated with shNDUFA4L2.2 was not as 
high as in RCC4 cells treated with shNDUFA4L2.1 or shNDUFA4L2.2 
(Supplementary Fig. S4B and Fig. 5D). Additionally, we did not detect an 
increase in LC3-II levels in Caki1, 786-O, or HK2 cells treated with either 
shNDUFA4L2 construct (Supplementary Fig. S5).  
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Discussion 
 Altered metabolism is a major characteristic of ccRCC. We recently 
reported on the importance of HIF1α in mediating altered tumor metabolism in 
the TRACK model of ccRCC, similar to the changes observed in human ccRCC 
(10, 16). Targeting pathways that mediate altered metabolism may provide novel 
and more effective treatments (2, 17). In this study, we demonstrated that a 
HIF1α target gene involved in mediating glycolysis, NDUFA4L2, is highly 
expressed at the mRNA and protein levels in human ccRCC, yet is not 
expressed in normal kidney tissue (Table 1 and Fig. 1). We also showed that 
NDUFA4L2 mRNA levels are greater in the more advanced staged and graded 
ccRCCs (Fig. 1C, D), and that patients with the highest expression of NDUFA4L2 
in their tumors exhibit a lower overall survival rate (Fig. 1E). Moreover, we found 
that NDUFA4L2 knockdown leads to a profound decrease in proliferation and 
colony formation In HIF1α positive cell lines (Fig. 3). Collectively, these data 
demonstrate NDUFA4L2 is an attractive therapeutic target to treat ccRCC. 
 Previous work on NDUFA4L2 is limited. In the one major study 
charactering NDUFA4L2, Tello et al demonstrated that NDUFA4L2 is a direct 
HIF1α target gene (18). By assessing NDUFA4L2 expression in our various 
murine models, we confirmed that NDUFA4L2 is regulated by HIF1α, but not 
HIF2α  (Fig. 2). Although deletion of HIF1α  has previously been reported in 
ccRCC (39, 40), the results shown here and available in the TCGA-KIRC 
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RNAseq expression data support an important role for HIF1α, acting in part via 
NDUFA4L2, in the majority of human ccRCCs (34).  
 We and others have shown that HIF1α mediates the Warburg effect in 
ccRCC, a phenomenon in which cancer cells rely on aerobic glycolysis to 
generate ATP instead of the TCA cycle and oxidative phosphorylation (10, 16, 
41). Tello et al showed that NDUFA4L2 inhibits complex I of oxidative 
phosphorylation to mediate a shift to glycolysis (18). Thus, it is likely that 
NDUFA4L2 has a role in mediating the Warburg effect in ccRCC. Interestingly, 
aerobic glycolysis is a less efficient method for producing ATP. One explanation 
for why aerobic respiration is favored is that proliferating cancer cells not only 
require ATP, but also need nucleotides, fatty acids, and proteins (35). 
Reprogrammed metabolism supports the synthesis of these macromolecules 
required for rapid proliferation (35). We demonstrated that NDUFA4L2 is 
important for supporting ccRCC metabolism to generate nucleic acids (Fig. 4). 
Nucleic acids, which include DNA and RNA, are vital building blocks for cell 
growth and division. Thus, it is likely that NDUFA4L2 knockdown impairs 
proliferation in ccRCC cells, at least in part, by disrupting the synthesis of critical 
macromolecules, DNA and RNA. 
 Cancer cells that have reduced aerobic respiration frequently display 
abnormalities in both the content and composition of their mitochondria (36). In 
parental RCC4 and RCC4 shCTL treated cells we visualized swollen 
mitochondria with abnormal, disorganized cristae (Fig. 5). As mitochondrial 
morphology and function are closely linked (42), these data suggest that these 
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cells have diminished mitochondrial capacity. However, when NDUFA4L2 levels 
are reduced, we found that the mitochondrial structures improve and the cristae 
become less disorganized (Fig. 5). These findings, and the metabolomics data 
indicating that TCA cycle intermediates are increased upon NDUFA4L2 
knockdown (Fig. 3), suggest that mitochondrial bioenergetics are improved when 
NDUFA4L2 levels are reduced. The restoration of mitochondrial bioenergetics is 
currently being pursued as an approach for treating a variety of different diseases, 
including aging-related diseases. SS-31, a mitochondrial-targeted peptide, is one 
example of a compound that protects mitochondrial cristae and promotes ATP 
synthesis by interacting with cardiolipin, an inner mitochondrial membrane 
phospholipid that has a central role in in the structure and organization of cristae 
(43). Interestingly, SS-31 was shown to protect the kidneys of rats after ischemia 
(44). Similar to our data, treatment with SS-31 resulted in more normal and 
elongated mitochondria with finely stacked cristae membranes (44). Targeting 
mitochondrial biogenesis for the treatment of ccRCC has not been well studied, 
and SS-31 has not been tested in the context of this disease. However, based on 
our data from knocking down NDUFA4L2 in ccRCC cells and the success of SS-
31 in protecting rat kidneys from ischemia, further research into improving 
mitochondria bioenergetics in the context of active HIF1α  as a treatment for 
ccRCC is warranted.   
 Mitochondrial turnover is dependent on the intracellular degradation 
process autophagy (38), which we detected in the ccRCC cells uponNDUFA4L2 
knockdown (Fig. 5). Thus it is possible that autophagy is induced in NDUFA4L2 
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knockdown cells to remove the damaged mitochondria in order to generate more 
functional mitochondria. Another potential explanation for the induction of 
autophagy in the RCC4 and SKRC48 NDUFA4L2 knockdown cells is that the 
cells are nutrient-deprived when NDUFA4L2 levels are diminished. It is well 
established that autophagy is induced under starvation or serum deprivation (38), 
and although nutrients are readily available to NDUFA4L2 knockdown cells in 
culture, their ability to metabolize nutrients is altered (Fig. 4). While further 
experiments are required to delineate the exact influence of NDUFA4L2 
knockdown on autophagy, it is clear that NDUFA4L2 knockdown causes major 
stress on RCC4 and SKRC48 cells.  
  ccRCC is characterized as a highly metabolic disease and alterations in 
metabolism are likely to be fundamental to the development of advanced ccRCC 
(3). Thus, targeting the metabolic basis of ccRCC could be an effective strategy 
for treating the disease (17, 45-47).  
 Targeting NDUFA4L2 for inhibition to treat ccRCC has several advantages. 
To start, NDUFA4L2 is an appealing target because it is so frequently and highly 
expressed in ccRCC but is not normally expressed in kidney tissue or other 
tissues of the body. Additionally, targeting NDUFA4L2 should not disrupt 
glycolysis in normal cells. Many of the other genes involved in increasing the rate 
of glycolysis in cancer cells encode enzymes that also play critical roles in non-
transformed cells, and thus inhibiting them could harm healthy, normal cells. For 
these reasons, and because of our data showing that NDUFA4L2 knockdown 
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profoundly inhibits ccRCC proliferation, we propose that NDUFA4L2 is a novel 
molecular target for inhibition to be pursued for the treatment of ccRCC.  
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Table: 
 
Table 1. Summary of four studies that collected microarray data and TCGA 
RNAseq data from ccRCC samples and adjacent non-tumor samples. *For 
TCGA data, q-value is listed instead of p-value.  
Reference ccRCC samples 
Non-tumor 
samples 
NDUFA4L2 fold 
change in ccRCC p-Value 
Gumz et al (12) 10 10 53.935 2.60 x 10-11 
Jones et al (15) 23 23 8.361 7.32 x 10-8 
Yusenko et al (14) 26 3 86.564 7.04 x 10-15 
Lenburg et al (13) 9 9 23.340 5.51 x 10-9 
TCGA (17) 530 72 49.121 3.06 x 10-105 * 
 
Figure Legends: 
Figure 1. NDUFA4L2 expression is elevated in ccRCC and is clinically 
significant.  
(A) NDUFA4L2 mRNA levels (left panel) and NDUFA4L2 and NDUFA4 protein 
levels (right panel) in human ccRCC samples vs. matched normal kidney tissue. 
(B) Levels of NDUFA4L2 mRNA (left panel) and NDUFA4L2 and NDUFA4 
protein (right panel) in several human ccRCC cell lines and in HK2 cells, a 
normal, non-transformed, proximal tubule cell line. For semiquantitative RT-PCR, 
HPRT mRNA is used as a loading control. For Western blot analysis β-actin is 
the loading control. Results are representative of experiments performed on 
three separate occasions with fresh cells (n=3) with similar results. (C) 
NDUFA4L2 mRNA levels in normal kidney tissue and in each American Joint 
(AJCC) stage of ccRCC as reported by TCGA. (D) NDUFA4L2 mRNA levels in 
normal kidney tissue and in each Fuhrman grade of ccRCC as reported by TCGA.  
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The expression values are the normalized NDUFA4L2 counts. The results are 
presented as mean ± standard error of the mean (SEM). Data were analyzed in 
EdgeR to generate a q-values. (E) A Kaplan-Meier curve to compare the overall 
survival of patients with low NDUFA4L2 expression (normalized count < 60,000, 
n = 448) versus high expression (normalized count > 60,000, n =60). The p-value 
was generated using the log-rank test. 
Figure 2. NDUFA4L2 expression is mediated specifically by HIF1α in 
TRACK kidneys. 
(A) Expression of NDUFA4L2 mRNA (left panel) and protein (right panel) in 
kidney tissue from the TRACK model, ϒ-HIF2αM3 TG+ mice, and TG- mice. (B) 
NDUFA4L2 protein expression in various tissues of the TRACK model. For 
semiquantitative RT-PCR, 36B4 mRNA is used as a loading control. For Western 
blot analysis β-actin is the loading control. Western blot and RT-PCR were 
performed on three or more mice (n≥3) and results are representative of triplicate 
experiments with similar results.  
Figure 3. Effective knockdown of NDUFA4L2 (13 kDa) in RCC4 and SKRC48 
cells with shRNA impairs cellular proliferation and colony formation.  
(A) Western blot analysis of NDUFA4L2 levels in RCC4 and SKRC48 parental 
cell lines and cells treated with NDUFA4L2 specific shRNA (see Materials and 
Methods for sequences) for 24 hours followed by a 96 hour selection with 
puromycin. NDUFA4L2 (13 kDa) is knocked down by greater than 95% in RCC4 
cells and greater than 98% in SKRC48 cells following treatment with 
shNDUFA4L2 constructs 1 and 2 and is unchanged when cells are infected with 
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a non-targeting construct (shCTL). β-actin was used as a loading control. (B) Cell 
proliferation assays of RCC4 and SKRC48 cells after viral infection with shRNA 
and selection. Data are the average of three independent experiments (n=3) and 
error bars represent SEM. (C) Colony formation of RCC4 and SKRC48 parental 
cells and cells treated with the indicated viral shRNA for 24 hours followed by 
selection with puromycin for 96 hours. Representative plates of experiments 
performed at least three times (n=3) with fresh cells are shown. (D) Graph of the 
number of colonies formed (expressed as mean ± SEM). ** p < 0.01; *** p < 
0.005; **** p < 0.0001. 
Figure 4. Knockdown of NDUFA4L2 causes metabolic alterations. 
(A) Comparison of the levels of the TCA cycle intermediates citrate/isocitrate, α-
ketoglutarate, succinate, and oxaloacetate in parental RCC4 cells and cells 
infected with the indicated shRNA constructs for 24 hours followed by puromycin 
for 96 hours. (B) Comparison of the levels of the pentose phosphate pathway 
intermediates ribose 5-phosphate, sedoheptulose 7-phosphate, glyceraldehyde 
3-phosphate, and fructose 6-phosphate in parental RCC4 cells and cells infected 
with the indicated shRNA constructs for 24 hours followed by puromycin for 96 
hours. (C) Schematic overview of the changes in the TCA cycle and pentose 
phosphate pathway upon treatment with shNDUFA4L2.1 in RCC4 cells. Arrows 
next to metabolites indicate that the metabolite levels are changed in 
shNDUFA4L2.1 treated cells compared to parental and shCTL treated cells. 
Metabolomics analysis was performed on samples in triplicate (n=3 for each 
group) and data are graphed as the mean ± SEM. ** p < 0.01; **** p < 0.0001. 
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Figure 5. NDUFA4L2 knockdown improves mitochondrial morphology and 
induces autophagy in RCC4 cells. 
(A) Representative images from transmission electron microscopy of RCC4 
parental cells and cells infected with the indicated shRNA constructs for 24 hours 
followed by puromycin for 96 hours. Filled arrows point to swollen mitochondria 
with disorganized cristae, open arrows point to contracted mitochondria with 
improved cristae, filled stars indicate autophagosomes, and open stars indicate 
autolysosomes. Magnification, 25000 x. Scale bar on the bottom left represents 2 
μm. (B) Quantification of the percentages of swollen mitochondria with 
disorganized cristae compared to the percentages of contracted mitochondria 
with improved cristae. (C) Quantification of the number of mitochondria per 100 
μm2. (D) Quantitation of the number of autophagosomes and autolysosomes per 
100 μm2 in RCC4 cells. (E) Western blot analysis of LC3 in RCC4 and SKRC48 
cell lines following 24 hours of shRNA treatment, 96 hours of puromycin selection, 
and a 5 day, untreated, incubation period. β-actin was used as loading control. 
Quantification of TEM data was performed in a blinded manner. Data were 
collected from three images from five different cells (15 images/cell type) and 
graphed as mean ± SEM. ** p < 0.01; *** p< 0.005; **** p < 0.0001; n.s. p>0.05. 
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